Free tool
FAERS Monitor: Metaxalone
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022503 or its brand name (Metaxalone, Metaxalone). Reports on generic versions are filed under their own applications.
Reports
3,351
Serious
2,080
62% of reports
Hospitalization
793
Death reported
605
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- completed suicide261
- drug ineffective208
- pain201
- nausea199
- fatigue198
- headache172
- toxicity to various agents164
- fall159
- diarrhoea135
- dizziness123
- dyspnoea122
- death117
- vomiting113
- chronic kidney disease111
- renal failure107
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 29 |
| 2005 | 46 |
| 2006 | 23 |
| 2007 | 28 |
| 2008 | 71 |
| 2009 | 23 |
| 2010 | 48 |
| 2011 | 75 |
| 2012 | 105 |
| 2013 | 172 |
| 2014 | 159 |
| 2015 | 283 |
| 2016 | 322 |
| 2017 | 240 |
| 2018 | 270 |
| 2019 | 366 |
| 2020 | 342 |
| 2021 | 179 |
| 2022 | 153 |
| 2023 | 96 |
| 2024 | 107 |
| 2025 | 135 |
| 2026 | 79 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,808 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| completed suicideSignal | 261 | 19.7 | 17.5 | 4,623 |
| chronic kidney diseaseSignal | 111 | 9.2 | 7.6 | 803 |
| toxicity to various agentsSignal | 164 | 6.1 | 5.3 | 701 |
| renal failureSignal | 107 | 5.1 | 4.2 | 346 |
| fallSignal | 159 | 3.0 | 2.6 | 213 |
| painSignal | 201 | 2.1 | 1.8 | 111 |
| headache | 172 | 1.7 | 1.5 | 53 |
| fatigue | 198 | 1.6 | 1.4 | 45 |
| nausea | 199 | 1.6 | 1.4 | 43 |
| dizziness | 123 | 1.5 | 1.3 | 24 |
| vomiting | 113 | 1.5 | 1.3 | 19 |
| dyspnoea | 122 | 1.4 | 1.1 | 11 |
| diarrhoea | 135 | 1.3 | 1.1 | 10 |
| drug ineffective | 208 | 1.0 | 0.9 | 0 |
| death | 117 | 0.9 | 0.7 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.